ACM
NBIX icon

Adalta Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Adalta Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,615
Closed -$251K – 99
2020
Q4 		$251K Buy
+2,615
New +$253K 0.16% 60

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Adalta Capital Management's NBIX Position: Q1 2021 in Review

Adalta Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2021, closing a stake of 2,615 shares — an estimated $251K sold.

Adalta Capital Management first reported a position in NBIX in Q4 2020 and held it in 1 quarter. The position peaked at $251K in Q4 2020. 420 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

  • Adalta Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2021 after selling out during the quarter.
  • Adalta Capital Management sold 2,615 Neurocrine Biosciences shares in Q1 2021, an estimated $251K.
  • Adalta Capital Management first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 1 quarter.
  • Adalta Capital Management's Neurocrine Biosciences position peaked at $251K in Q4 2020.
  • 420 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on Adalta Capital Management's 13F filing for Q1 2021, filed 18 May 2021.